Similar articles

• Cost effectiveness of prostacyclins in pulmonary arterial hypertension.

  Roman A, Barberà JA, Escribano P, Sala ML, Febrer L, Oyagüez I, Sabater E, Casado MA. Roman A, et al. Appl Health Econ Health Policy. 2012 May 1;10(3):175-88. doi: 10.2165/11630780-000000000-00000. Appl Health Econ Health Policy. 2012. PMID: 22452448 Review.
• [Therapy of severe pulmonary hypertension with prostacyclin and iloprost].

  Matthes J, Mathen F, Herzig S, Wassermann K. Matthes J, et al. Dtsch Med Wochenschr. 2001 May 25;126(21):631-7. doi: 10.1055/s-2001-14422. Dtsch Med Wochenschr. 2001. PMID: 11413752 Review. German. No abstract available.
• Epoprostenol use for pulmonary arterial hypertension in the palliative care setting.

  Wozencraft CP, Coyne PJ, Grinnan DC, Morel TD, Muzevich KM, Smith TJ. Wozencraft CP, et al. J Palliat Med. 2012 May;15(5):619-22. doi: 10.1089/jpm.2011.0182. Epub 2012 Mar 6. J Palliat Med. 2012. PMID: 22394366
• Acute pulmonary hypertensive crisis in a patient with primary pulmonary hypertension treated by both epoprostenol (prostacyclin) and nitroprusside.

  Scott JP, Higenbottam TW, Smyth RL, Wallwork J. Scott JP, et al. Chest. 1991 May;99(5):1284-5. doi: 10.1378/chest.99.5.1284. Chest. 1991. PMID: 2019196
• Epoprostenol for primary pulmonary hypertension.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 1996 Feb 16;38(968):14-5. Med Lett Drugs Ther. 1996. PMID: 8592477